Thiophenylaminoimidazolines as IP antagonists

Details Thiophenylaminoimidazolines as IP antagonists Thiophenylaminoimidazolines as IP antagonists

2006-07-18

2006-07-18

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S398000, C544S139000, C548S333100

Reexamination Certificate

active

07078401

ABSTRACT:
Methods for treatment of IP antagonist mediated diseases or conditions by administration to a subject in need thereof a compound of formula (I)wherein R1, R2, A and X are as defined herein. Also disclosed are compounds and related compositions.

REFERENCES:
patent: 4374143 (1983-02-01), Dolman et al.
patent: 4396617 (1983-08-01), Dolman et al.
patent: 6184242 (2001-02-01), Bley et al.
patent: 6417186 (2002-07-01), Jahangir
patent: 6472536 (2002-10-01), Bley et al.
patent: 6596876 (2003-07-01), Bley et al.
patent: 0 901 018 (1999-03-01), None
patent: WO 02/40453 (2002-05-01), None
Ito et al. Chem. & Pharm. Bull. 1960, 7, 605 *(CAS Abstract Attached).
Clarke, Robin D., “Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists”,Bioorganic&Medicinal Chemistry Letters, 14(4) 1053-1056, Feb. 23, 2004.

Affiliated with

Also associated with

Rating

Thiophenylaminoimidazolines as IP antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiophenylaminoimidazolines as IP antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiophenylaminoimidazolines as IP antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3595962